Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 9/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | MPC2 | O95563 | 2/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786497 | 0.88 | HPGD (0.67) | HPGDKMT2ACYP3A4MEN1ALDH1A1 | |
| SCHEMBL1070520 | 0.85 | CYP3A4 (0.77) | HPGDKMT2ACYP3A4MEN1ALDH1A1 | |
| SCHEMBL12521788 | 0.74 | CYP3A4 (0.75) | HPGDKMT2ACYP3A4MEN1ALDH1A1 | |
| SCHEMBL8651084 | 0.74 | HPGD (0.40) | HPGDKMT2ACYP3A4MEN1ALDH1A1 | |
| SCHEMBL11088249 | 0.72 | CYP3A4 (0.79) | HPGDKMT2ACYP3A4MEN1ALDH1A1 | |
| Ciglitazone SCHEMBL38185 | 0.71 | HPGD (1.00) | HPGDKMT2ACYP3A4MEN1ALDH1A1 | |
| Ciglitazone SCHEMBL20125581 | 0.71 | HPGD (1.00) | HPGDKMT2ACYP3A4MEN1ALDH1A1 | |
| Ciglitazone SCHEMBL20125576 | 0.71 | HPGD (1.00) | HPGDKMT2ACYP3A4MEN1ALDH1A1 | |
| SCHEMBL12521810 | 0.71 | CYP3A4 (0.61) | HPGDKMT2ACYP3A4MEN1ALDH1A1 | |
| SCHEMBL8651087 | 0.71 | HPGD (0.42) | HPGDKMT2ACYP3A4MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1006794-B1 | A METHOD FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE | ESMOND ROBERT W (US) | 2007-11-28 | — | — | EP | claimed |
| US-20060030597-A1 | Method of inhibiting angiogenesis | GERRITSEN MARY E | 2006-02-09 | — | — | US | claimed |
| US-6552055-B2 | Peroxidsome proliferator activated receptors | DANA-FARBER CANCER INSTITUTE | 2003-04-22 | — | — | US | claimed |
| US-20020106796-A1 | PAX8-PPARgamma nucleic acid molecules and polypeptides and uses thereof | BRIGHAM AND WOMEN'S HOSPITAL, INC., THE | 2002-08-08 | — | — | US | claimed |
| US-20010036955-A1 | Method of inhibiting angiogenesis | GENENTECH, INC. | 2001-11-01 | — | — | US | claimed |
| WO-2001052789-A2 | PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-07-26 | — | — | WO | claimed |
| US-6207690-B1 | TREATING TUMOR BY ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF TRIGLITAZONE COMPOUND | BOARD OF REGENTS, THE UNIVERSITY TEXAS SYSTEM | 2001-03-27 | — | — | US | claimed |
| EP-1014982-A4 | TROGLITAZONE COMPOUNDS FOR TREATING CLIMACTERIC | UNIV TEXAS (US) | 2001-01-31 | — | — | EP | claimed |
| EP-1014982-A1 | TROGLITAZONE COMPOUNDS FOR TREATING CLIMACTERIC | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1998039006-A1 | TROGLITAZONE COMPOUNDS FOR TREATING CLIMACTERIC | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-09-11 | — | — | WO | claimed |
| EP-0719140-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | Sankyo Company Limited (JP) | 1996-07-03 | — | — | EP | claimed |
| WO-1995007694-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | SANKYO COMPANY, LIMITED (JP) | 1995-03-23 | — | — | WO | claimed |
| US-20110300129-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2011-12-08 | — | — | US | disclosed |
| EP-1637138-B1 | Use of thiazolidinediones to prevent or delay onset of NIDDM | DAIICHI SANKYO CO LTD (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-1133294-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES | UNIV CASE WESTERN RESERVE (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010075037-A1 | SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY | UNIVERSITY OF ROCHESTER (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-1998025598-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING TUMOUR CELL GROWTH | DANA-FARBER CANCER INSTITUTE (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0719140-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | Sankyo Company Limited (JP) | 1996-07-03 | — | — | EP | disclosed |
| US-5478852-A | Administering | SANKYO COMPANY, LIMITED (JP) | 1995-12-26 | — | — | US | disclosed |
| WO-1995007694-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | SANKYO COMPANY, LIMITED (JP) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030597-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | HPGD 200/4885KMT2A 3484/4885CYP3A4 2854/4885 |
| US-20010036955-A1 | Method of inhibiting angiogenesis | PPARG, PPARA, RXRG | HPGD 200/4885KMT2A 3484/4885CYP3A4 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.